Ovarian reserve in breast cancer: assessment with anti-Mullerian hormone

REPRODUCTIVE BIOMEDICINE ONLINE

卷:29

Article

Hamy, Anne-Sophie¹  Porcher, Raphael^2,3  Cuvier, Caroline¹  Giacchetti, Sylvie¹  Schlageter, Marie-Helene⁴  Coussieu, Christiane^5,6  Gronier, Heloise¹  Feugeas, Jean-Paul⁷  Adoui, Nadir⁷  Lacorte, Jean-Marc^5,6  Poirot, Catherine⁸  Habdous, Mohamed¹  Espie, Marc¹ 

[1] Hop St Louis, AP HP, Ctr Malad Sein, F-75010 Paris, France

[2] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, F-75004 Paris, France

[3] INSERM, F-75475 Paris 10, France

[4] Hop St Louis, AP HP, Serv Biol Cellulaire, F-75010 Paris, France

[5] Grp Hosp Pitie Salpetriere, AP HP, UF Nutrigenet, Serv Biochim Endocrinienne & Oncol, F-75651 Paris, France

[6] U872 INSERM Equipe 4, F-75006 Paris, France

[7] Hop St Louis, AP HP, Serv Biochim, Lab Urgences & Gardes, F-75010 Paris, France

[8] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP, Serv Biol Reprod, F-75651 Paris, France

关键词: AMH;    breast cancer;    chemotherapy;    ovarian reserve;   

DOI  :  10.1016/j.rbmo.2014.07.008

来源: Elsevier

【 摘 要 】

Anti-Mullerian hormone (AMH) levels fall during chemotherapy. Treatment-induced amenorrhoea is a reversible phenomenon, but few data are available on long-term AMH changes in breast cancer. The aim of the study was to describe serum AMH levels before, during and in the long term after chemotherapy, and to show a potential AMH recovery. Between May 2010 and June 2011, we selected 134 women aged 18-43 years at the time of breast cancer diagnosis who received chemotherapy between 2005 and 2011, and had not undergone an oophorectomy or had previous cytotoxic treatment. The AMH levels were assessed before, during and 4 months to 5.5 years after the end of chemotherapy. During chemotherapy, AMH was undetectable in 69% of women. After chemotherapy, a significant increase in AMH was found, with an average magnitude of + 1.2% per month (95% credibility interval: 0.7 to 1.6). Older age and 12 months of amenorrhoea were found to be associated with a lower AMH recovery rate, whereas baseline AMH and number of chemotherapy cycles were not. The process of AMH changes during and after chemotherapy is dynamic, and shows recovery after ovarian injury. Caution should be exercised in interpreting individual AMH assessment in this context. (C) 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

【 授权许可】

Free